A phase II study of maintenance therapy with WT1 peptide-based cancer vaccine following the first-line therapy for advanced-stage ovarian cancer
- Conditions
- Ovarian cancer
- Registration Number
- JPRN-UMIN000011859
- Lead Sponsor
- Osaka university graduate school of medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 55
Not provided
1) Residual diseases after surgical and chemotherapy 2) Received intra-peritoneum chemotherapy 3) Active other cancers except for carcinoma in situ treated completely 4) Received Immunosuppresive agents actively at registration 5) Received Growth factor, including G-CSF, Epo, TPO, within 14 days before registration 6) Received other tested agents within 28 days before registration 7) Received WT1 vaccine 8) Past history of Myeloproliferative diseases, MSD 9) Past history of pulmonary fibrosis, interstitial pneumonitis 10) Past history of autoimmune diseases, including collagen diseases 11) Severe Complications, including Heart failure, Renal faiure, Hapatic failure, ileus, uncontrolable DM, and so on 12) active infectious diseases 13) Past history of HIV, HBV, and HCV infections 14) Grade 3 or severer Neutopatic complications 15) Hypersensitivity to some drugs 16) Pregnancy / lactation 17) Severe Psychological Problems 18) Other severe problems unsuitable for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 2-year disease free survival rate
- Secondary Outcome Measures
Name Time Method overall survival, antigen-specific immunity, safety, and so on